We broke the pharma lock. Royalties from patents, biobanks & clinical trials — fractionalized into vials anyone can hold. Real assets, real yield, on-chain.
Unveiled at DeSci Berlin 2026, OpenLabs fuses AI-assisted research, community funding and on-chain governance as Bio's ecosystem surpasses $33M raised via BIO Genesis.
Read at crypto.newsSeed round joined by Mechanism Capital and Animoca Brands. First BioAgent "Aubrai" — built with VitaDAO — minted 1,000+ hypotheses on-chain; its token ran 150x.
Read at The BlockBio V2 introduces on-chain fundraising, staking and agentic AI. Since 2024 the network has directed $50M+ to labs worldwide, an alternative amid global funding cuts.
Read at bio.xyzOver 50 active DeSci projects worldwide have now attracted $60M+ in combined institutional and community funding, using community ownership to bypass grant bottlenecks.
Read at Berkeley"2026 will see DeSci become much more than a perceived niche." A look at maturing DAO governance, IP-NFT enforceability and the compliance rails coming next.
Read the essayGranted through Bio Protocol's bio/acc rewards program, the allocation lets VitaDAO govern curation, funding and liquidity across the broader bioDAO ecosystem.
Read at VitaDAO